Skip to main content
SpringerLink
Log in

Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy

  • Neuro-Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Current treatments in grade III gliomas include surgery, radiotherapy, and chemotherapy. The value of the entity of surgical resection remains an open question. The aim of this evaluation was to analyze the impact of extent of resection (EOR) and residual tumor volume (RTV) on progression-free survival (PFS) and overall survival (OS) in patients with newly diagnosed grade III gliomas.

Methods

Overall, 136 patients were included in this evaluation. EOR and RTV were defined in all patients on postoperative volumetric magnetic resonance imaging, with EOR being defined as the rate of surgical resection, and RTV as contrast-enhancing RTV (CE-RTV) and fluid-attenuated inversion recovery (FLAIR) RTV. A threshold of EOR and RTV was recorded using increments of 2 % and 1 cm3.

Results

EOR and RTV were the only clinical variables influencing PFS and OS. The EOR cut-off value for conditioning survival was 76 %. For EOR ≥76 % or <76 %, the 5- to 10-year PFS was 57 % and 18 % versus 0 % (p = 0.03), and 5- to 10-year OS was 68 % and 42 % versus 0 % (p = 0.06), respectively. Additionally, the RTV cut-off value was 3 cm3; for RTV <3 cm3 or >3 cm3, 5- to 10-year PFS was 64.3 % and 48.2 % versus 42 % and 0 % (p = 0.02), and 5- to 10-year OS was 66.8 % and 33.4 % versus 56 % and 0 % (p = 0.3), respectively. RTV was a more significant parameter conditioning PFS and OS than EOR (p = 0.04), and the presence of CE-RTV was an unfavorable prognostic factor compared with FLAIR-RTV.

Conclusions

In heterogeneous lesions from a radiological point of view as WHO grade III gliomas if a complete removal is not possible, it would be advisable to maximize the removal of enhancing areas, possibly with an EOR >76 % and an RTV <3 cm3.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Brell M, Tortosa A, Verger E, et al. Prognostic significance of O6-methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005;11:5167–74.

    Article  CAS  PubMed  Google Scholar 

  2. Bauman G, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys. 2000;48:825–30.

    Article  CAS  PubMed  Google Scholar 

  3. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol. 2003;61:267–73.

    Article  PubMed  Google Scholar 

  4. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol. 2003;64:271–78.

    Article  PubMed  Google Scholar 

  5. Jiang H, Ren X, Cui X, et al. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. Neuro Oncol. 2013;15:775–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Frenel J, Leux C, Loussouarn D, et al. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. J Neurooncol. 2013;114:85–91.

    Article  CAS  PubMed  Google Scholar 

  7. Olar A, Wani K, Alfaro-Munoz K, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathol. 2015;129:585–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. The Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–98.

    Article  Google Scholar 

  9. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol. 2009;35:5874–80.

    Article  Google Scholar 

  10. Yamaguchi S, Kobayashi H, Terasaka S, et al. The impact of extent of resection and histological subtype on the outcome of adult patients with high-grade gliomas. Jpn J Clin Oncol. 2012;42(4)270–77.

    Article  PubMed  Google Scholar 

  11. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110:156–62.

    Article  PubMed  Google Scholar 

  12. Cohen ZR, Suki D, Shi W, et al. Surgical resection of anaplastic astrocytoma: prognostic factors and outcome. Neuro Oncol. 2002;4:367–72

    Google Scholar 

  13. Castellano A, Bello L, Michelozzi C, et al. Role of diffusion tensor magnetic resonance tractography in predicting the extent of resection in glioma surgery. Neuro Oncol. 2012;14:192–202.

    Article  PubMed  Google Scholar 

  14. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62:753–64.

    Article  PubMed  Google Scholar 

  15. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338–45.

    Article  PubMed  Google Scholar 

  16. Chaichana KL, Jusue-Torres L, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014;16:113–22.

    Article  PubMed  Google Scholar 

  17. Grabowski MM, Recinos PF, Nowacki AS, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014;121:1115–23.

    Article  PubMed  Google Scholar 

  18. Smith JS, Cha S, Mayo MC, et al. Serial diffusion-weighted magnetic resonance imaging in cases of glioma: Distinguishing tumor recurrence from postresection injury. J Neurosurg. 2005;103:428–38.

    Article  PubMed  Google Scholar 

  19. Wen P, Macdonald D, Reardon D, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72.

    Article  PubMed  Google Scholar 

  20. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurg. 2008;62:564–76.

    Article  Google Scholar 

  21. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115:3–8

    Article  PubMed  Google Scholar 

Download references

Disclosure

Luca Cozzi acts as a Scientific Advisor to Varian Medical Systems and is Clinical Research Scientist at Humanitas Cancer Center. Federico Pessina, Pierina Navarria, Anna Maria Ascolese, Matteo Simonelli, Armando Santoro, Stefano Tomatis, Marco Riva, Enrica Fava, Marta Scorsetti, and Lorenzo Bello have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy

    Federico Pessina MD, Marco Riva MD, Enrica Fava MD & Lorenzo Bello MD

  2. Department of Radiotherapy, Istituto Clinico Humanitas, Milan, Italy

    Pierina Navarria MD, Luca Cozzi PhD, Anna Maria Ascolese MD, Stefano Tomatis MSc & Marta Scorsetti MD

  3. Department of Oncology and Hematology, Istituto Clinico Humanitas, Milan, Italy

    Matteo Simonelli MD & Armando Santoro MD

Authors
  1. Federico Pessina MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierina Navarria MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luca Cozzi PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Maria Ascolese MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matteo Simonelli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Armando Santoro MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stefano Tomatis MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marco Riva MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Enrica Fava MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Marta Scorsetti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lorenzo Bello MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luca Cozzi PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pessina, F., Navarria, P., Cozzi, L. et al. Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy. Ann Surg Oncol 23, 3040–3046 (2016). https://doi.org/10.1245/s10434-016-5222-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5222-3

Keywords

Search

Navigation